Table I.
Analysis of HDAC6 staining patterns with various clinicopathological characteristics and PD-L1 status.
| HDAC6 expression | |||||
|---|---|---|---|---|---|
| Clinicopathological characteristic | Total | Nuclear | Nuc+cyt | Cytoplasmic | Negative |
| Total (%) | 97 | 5 (5.2) | 36 (37.1) | 54 (55.7) | 2 (2.1) |
| T stage, n (%) | |||||
| pTa | 52 | 4 (7.7) | 21 (40.4) | 27 (51.9) | 0 (0.0) |
| pT1 | 25 | 1 (4.0) | 8 (32.0) | 14 (56) | 2 (8.0) |
| >pT2 | 14 | 0 (0.0) | 4 (28.6) | 10 (71.4) | 0 (0.0) |
| Tis | 6 | 0 (0.0) | 3 (50.0) | 3 (50.0) | 0 (0.0) |
| Grade, n (%) | |||||
| Low | 31 | 2 (6.4) | 13 (41.9) | 16 (51.6) | 0 (0.0) |
| High | 66 | 3 (4.6) | 23 (34.8) | 38 (57.6) | 2 (3.0) |
| PD-L1, n (%) | |||||
| Negative | 54 | 4 (7.4) | 18 (33.3) | 31 (57.4) | 1 (1.9) |
| Positive | 43 | 1 (2.3) | 18 (41.9) | 23 (53.5) | 1 (2.3) |
Nuc, nuclear; cyt, cytoplasmic; PD-L1, programmed death-ligand 1; HDAC, histone deacetylase.